These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 26831162)

  • 1. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
    Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
    J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of serum cardiac troponin I and acute phase protein concentrations with clinical staging in dogs with degenerative mitral valve disease.
    Polizopoulou ZS; Koutinas CK; Cerón JJ; Tvarijonaviciute A; Martínez-Subiela S; Dasopoulou A; York MJ; Roman IF; Gandhi M; Patel S; O'Brien PJ
    Vet Clin Pathol; 2015 Sep; 44(3):397-404. PubMed ID: 26288324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease.
    Zois NE; Moesgaard SG; Kjelgaard-Hansen M; Rasmussen CE; Falk T; Fossing C; Häggström J; Pedersen HD; Olsen LH
    Vet J; 2012 Apr; 192(1):106-11. PubMed ID: 21696985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
    Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
    Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
    Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs.
    Ljungvall I; Höglund K; Tidholm A; Olsen LH; Borgarelli M; Venge P; Häggström J
    J Vet Intern Med; 2010; 24(1):153-9. PubMed ID: 20002554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
    Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and its association with oxidative stress in dogs with heart failure.
    Nemec Svete A; Verk B; Čebulj-Kadunc N; Salobir J; Rezar V; Domanjko Petrič A
    BMC Vet Res; 2021 Apr; 17(1):176. PubMed ID: 33902566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
    Tidholm A; Ljungvall I; Höglund K; Westling AB; Häggström J
    J Vet Intern Med; 2009; 23(6):1197-207. PubMed ID: 19909428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.
    Vereb M; Atkins CE; Adin D; Blondel T; Coffman M; Lee S; Guillot E; Ward JL
    J Vet Intern Med; 2024; 38(1):51-60. PubMed ID: 37909399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum serotonin concentration is associated with severity of myxomatous mitral valve disease in dogs.
    Ljungvall I; Höglund K; Lilliehöök I; Oyama MA; Tidholm A; Tvedten H; Häggström J
    J Vet Intern Med; 2013; 27(5):1105-12. PubMed ID: 23865457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.